Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
2023年5月11日 - 8:00PM
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a
global leader in innovations for active healing, announced today
the Company plans to file Form 12b-25, Notification of Late Filing,
for its Quarterly Report on Form 10-Q for the period ended April 1,
2023, on May 11, 2023.
Due to complexity of its tax structure and the associated impact
on the calculation of noncontrolling equity interest in the equity
section of the Company’s balance sheet, additional time is required
to complete the calculation and file the Company’s financial
results.
The resulting noncontrolling equity calculations should have no
impact on the Company’s revenue or Adjusted EBITDA for the period.
At this time, the Company expects to report revenue for the quarter
ended April 1, 2023, of approximately $119 million and Adjusted
EBITDA of approximately $17 million. The Company expects to be in
compliance with all of its financial covenants under its bank
agreement as of the end of the quarter.
The Company now plans to report financial results for the first
quarter of fiscal year 2023 before the market opens on Tuesday, May
16, 2023, rather than Thursday, May 11, 2023, as previously
announced. The Company’s management will host a conference call at
8:30 a.m. Eastern Time on Tuesday, May 16, 2023, as well to discuss
the results and provide a business update.
To participate in the conference call, dial 1-833-636-0497
(domestic) or +1-412-902-4241 (international) and refer to the
Bioventus Inc. Conference Call.
As permitted by the Form 12b-25 filing, the Company expects to
file its Form 10-Q for the period ended April 1, 2023, by May 16,
2023.
About Bioventus
Bioventus delivers clinically proven, cost-effective products
that help people heal quickly and safely. Its mission is to make a
difference by helping patients resume and enjoy active lives. The
Innovations for Active Healing from Bioventus include offerings for
Pain Treatments, Restorative Therapies and Surgical Solutions.
Built on a commitment to high quality standards, evidence-based
medicine and strong ethical behavior, Bioventus is a trusted
partner for physicians worldwide. For more information, visit
www.bioventus.com, and follow the Company on LinkedIn and Twitter.
Bioventus and the Bioventus logo are registered trademarks of
Bioventus LLC.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements contained in this presentation that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements concerning the timing of the Company’s filing of its
Quarterly Report on Form 10-Q for the period ended October 1, 2022,
and the potential impacts (or lack thereof) of the calculation of
noncontrolling equity interest. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would” and other similar expressions
that are predictions of or indicate future events and future
trends, or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain
these words. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Factors that could cause our actual results to differ
materially from those contemplated in this press release include,
but are not limited to: our ability to file the Form 10-Q within
the extension period permitted by Form 12b-25; the risk that we
identify additional changes to our consolidated financial
statements; the risk that we discover material weaknesses in our
disclosure controls and procedures or internal controls over
financial reporting; we may not be able to continue fund our
operations for at least the next twelve months as a going concern;
risks related to our debt and future capital needs; and the other
risks identified in the Risk Factors section of the Company’s
public filings with the Securities and Exchange Commission (SEC),
including Bioventus’ Annual Report on Form 10-K for the year ended
December 31, 2022, and as may be further updated from time to time
in Bioventus’ other filings with the SEC, which are accessible on
the SEC’s website at www.sec.gov and the Investor Relations page of
Bioventus’ website at https://ir.bioventus.com. Except to the
extent required by law, the Company undertakes no obligation to
update or review any estimate, projection, or forward-looking
statement. Actual results may differ materially from those set
forth in the forward-looking statements.
Investor and Media Inquiries:Dave
Crawford919-474-6787dave.crawford@bioventus.com
Bioventus (NASDAQ:BVS)
過去 株価チャート
から 4 2024 まで 5 2024
Bioventus (NASDAQ:BVS)
過去 株価チャート
から 5 2023 まで 5 2024